Attached files
| file | filename |
|---|---|
| EX-99.2 - PRESS RELEASE, DATED APRIL 2, 2020. - NanoVibronix, Inc. | ea120510ex99-2_nanovibronix.htm |
| EX-99.1 - PRESS RELEASE, DATED APRIL 1, 2020. - NanoVibronix, Inc. | ea120510ex99-1_nanovibronix.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 1, 2020
NanoVibronix, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 001-36445 | 01-0801232 | |
| (Commission File Number) | (IRS Employer Identification No.) |
525 Executive Blvd., Elmsford, NY 10523
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (914) 233-3004
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company þ
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $0.001 per share | NAOV | Nasdaq Capital Market |
Item 8.01 Other Events.
On April 1, 2020, NanoVibronix, Inc. (the “Company”) issued a press release (the “April 1 Press Release”) announcing that the U.S. Centers for Medicare and Medicaid Services has approved the Company’s PainShield™ for reimbursement for Medicare beneficiaries on a national basis effective January 2020.
On April 2, 2020, the Company issued a press release (the “April 2 Press Release”) announcing that it signed a license agreement with Sanuwave Health, Inc. for the manufacture and delivery of the Company’s WoundShield technology.
The April 1 Press Release and the April 2 Press Release are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |
| 99.1 | Press Release, dated April 1, 2020. | |
| 99.2 | Press Release, dated April 2, 2020. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NANOVIBRONIX, INC. | ||
| Date: April 7, 2020 | By: | /s/ Brian Murphy |
| Name: Brian Murphy | ||
| Title: Chief Executive Officer | ||